Pfizer has reported its Q3 2025 results, revealing that newly launched and acquired products contributed USD 7.3 billion in incremental revenue, positioning the company to offset upcoming patent expirations. Total revenue for the first 9 months reached USD 45.0 billion, despite a 2% year-on-year (YoY) decline. The oncology segment showed strong growth at USD 12.4 billion, driven by products like breast cancer treatment Ibrance (palbociclib) and newer therapies, including the CD3×BCMA bispecific antibody Elrexfio (elranatamab). Revenue from Seagen-acquired assets such as the ADC drug Padcev (enfortumab vedotin) reached USD 1.4 billion, demonstrating the strategic value of recent purchases.

Beyond oncology, Pfizer's primary care business generated USD 18.9 billion, led by anticoagulant Eliquis (apixaban) and Prevnar vaccines, though Eliquis faces patent challenges in 2026. The company also highlighted an arrangement with the US government to ensure drug pricing alignment with developed markets and participation in a direct procurement platform offering discounted medications to US patients. Chairman and CEO Albert Bourla stated these concessions provide greater business clarity and strengthen Pfizer's ability to address significant medical needs while delivering value for patients and shareholders.

According to PharmCube's NextBiopharm® database, over the next 3 years Pfizer will see US patents expire for 17 commercialised products across a range of targets. Click here to request a free trial for NextBiopharm®.